Modern Pediatrics. Ukraine. (2025).6(150): 110-116. doi: 10.15574/SP.2025.6(150).110116
Zozulia O. V.^1,2, Dorosh O. I.^1,3, Dubey N. V.¹, Dubey L. Ya.^1
1Danylo Halytsky Lviv National Medical University, Ukraine
²Rivne Regional Children’s Hospital, Rivne, Ukraine
³Lviv Regional Children’s Clinical Center, Subdivision “Western Ukrainian Specialized Pediatric Medical Center”, Ukraine

For citation: Zozulia OV, Dorosh OI, Dubey NV, Dubey LYa. (2025). Аcute lymphoblastic leukemia in a child with Gaucher disease type 1 (сlinical сase). Modern Pediatrics. Ukraine. 6(150): 110-116. doi: 10.15574/SP.2025.6(150).110116.
Article received: Apr 11, 2025. Accepted for publication: Sep 16, 2025.

Aim – to investigate the features of the course of ALL in a child with GD1 and analyze the impact of both diseases on the clinical picture and the effectiveness of therapy.
This article presents a clinical case of the diagnosis and treatment GD1 and ALL in a five-year-old boy. The patient received enzyme replacement therapy (ERT) with imiglucerase for GD1. The disease manifested with hemorrhagic syndrome, intoxication syndrome, anemia, hepatosplenomegaly, and enlargement of peripheral lymph nodes. Hematological, cytological, immunological, and molecular-genetic studies were performed to establish the diagnosis. Treatment followed the ALL IC-BFM 2009 protocol, which included intensive chemotherapy complicated by thrombocytopenia, granulocytopenia, infectious and fungal complications, neuropathy, and cardiomyopathy. Allergic reactions to L-asparaginase were also observed. Despite these complications, genetic polymorphism indicated a favorable therapeutic response and an optimistic prognosis.
A comprehensive approach to managing a child with GD1 and ALL, taking into account the specifics of both conditions, enabled the creation of an individualized treatment plan aimed at achieving remission and improving the patient’s quality of life. The child is currently in clinical and genetic remission.
The study was conducted in accordance with the principles of the Declaration of Helsinki. Informed consent for the research was obtained from the child’s parents.
The authors declare no conflict of interest.
Keywords: Gaucher disease type 1, acute lymphoblastic leukemia, internal organ involvement, anemia, thrombocytopenia, hepatosplenic syndrome, enzyme replacement therapy, programmed hemoblastosis treatment.

REFERENCES

1. Dardis A, Michelakakis H, Rozenfeld P et al. (2022). Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1. Orphanet J. Rare Dis. 17: 442. https://doi.org/10.1186/s13023-022-02573-6; PMid:36544230 PMCid:PMC9768924

2. Dinur T, Bauer P, Beetz C et al. (2022). Gaucher disease diagnosis using Lyso-Gb1 on dry blood spot samples: Time to change the paradigm? Int. J. Mol. Sci. 23: 1627. https://doi.org/10.3390/ijms23031627; PMid:35163551 PMCid:PMC8835963

3. Ivanova M, Limgala R, Changsila E et al. (2018). Gaucheromas: When macrophages promote tumor formation and dissemination. Blood Cells Mol. Dis. 68: 100-105. https://doi.org/10.1016/j.bcmd.2016.10.018; PMid:27839983

4. Kong W, Lu C, Ding Y et al. (2022). Update of treatment for Gaucher disease. Eur. J. Pharmacol. 926: 175023. https://doi.org/10.1016/j.ejphar.2022.175023; PMid:35569551

5. Machaczka M, Paucar M, Björkvall C et al. (2018). Novel hyperkinetic dystonia-like manifestation and neurological disease course of Swedish Gaucher patients. Blood Cells Mol. Dis. 68: 86-92. https://doi.org/10.1016/j.bcmd.2016.10.011; PMid:27789132

6. Peterschmitt M, Crawford NPS, Gaemers SJM et al. (2021). Pharmacokinetics, pharmacodynamics, safety, and tolerability of oral venglustat in healthy volunteers. Clin. Pharmacol. Drug Dev. 10: 86-98. https://doi.org/10.1002/cpdd.865; PMid:32851809 PMCid:PMC7818513

7. Ramaswami U, Mengel E, Berrah A et al. (2021). Throwing a spotlight on under-recognized manifestations of Gaucher disease: Pulmonary involvement, lymphadenopathy and Gaucheroma. Mol. Genet. Metab. 133: 335-344. https://doi.org/10.1016/j.ymgme.2021.06.009; PMid:34229967

8. Schiffmann R, Sevigny J, Rolfs A et al. (2020). The definition of neuronopathic Gaucher disease. J. Inherit. Metab. Dis. 43: 1056-1059. https://doi.org/10.1002/jimd.12235; PMid:32242941 PMCid:PMC7540563

9. Stirnemann J, Belmatoug N, Camou F et al. (2017). A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int. J. Mol. Sci. 18: 441. https://doi.org/10.3390/ijms18020441; PMid:28218669 PMCid:PMC5343975

10. Suttorp M, Classen C. (2021). Splenomegaly in children and adolescents. Front. Pediatr. 9: 693. https://doi.org/10.3389/fped.2021.704635; PMid:34307263 PMCid:PMC8298754

11. Tseng S, Niu D, Chu T et al. (2019). Very rare condition of multiple Gaucheroma: A case report and review of the literature. Mol. Genet. Metab. Rep. 20: 100473. https://doi.org/10.1016/j.ymgmr.2019.100473; PMid:31193028 PMCid:PMC6514358

12. Weinreb N, Goker-Alpan O, Kishnani P et al. (2022). The diagnosis and management of Gaucher disease in pediatric patients: Where do we go from here? Mol. Genet. Metab. 136: 4-21. https://doi.org/10.1016/j.ymgme.2022.03.001; PMid:35367141

13. Yano S, Moseley K, Mahajan N. (2020). Large mesenteric Gaucheroma responds to substrate reduction therapy: a new management of Gaucheromas. J. Pediatr. Genet. 11: 47-50. https://doi.org/10.1055/s-0040-1714699; PMid:35186390 PMCid:PMC8847045

14. Derzhavnyi ekspertnyi tsentr Ministerstva okhorony zdorov'ia Ukrainy. (2023). Diahnostyka ta likuvannia hostroi limfoblastnoi leikemii u ditei ta pidlitkiv. Klinichna nastanova, zasnovana na dokazakh. Kyiv: DETs MOZ Ukrainy: 218.